The randomized, double-blind study evaluated the safety and tolerability of a 90 mg daily dose of NTRX-07. Researchers utilized diffusion MRI and cerebrospinal fluid analysis to track neurodegeneration and inflammation. Findings indicated that treated participants exhibited reduced neuroinflammatory markers, particularly in the superior parietal region. These imaging results were bolstered by stable or decreasing levels of neurofilament light chain in the treatment group, contrasting with increases observed in placebo participants.

Dr. Joseph Foss, Chief Medical Officer at NeuroTherapia, noted that the human data aligns with anti-inflammatory activity previously documented in animal models. The study also recorded an improved Aβ42/Aβ40 ratio, suggesting altered amyloid dynamics. CEO Tony Giordano stated that the company plans to leverage these signals to advance the oral small-molecule drug into subsequent stages of clinical development, while also exploring its potential application across other neuroinflammatory conditions such as ALS and multiple sclerosis. The trial received partial funding from the Alzheimer's Association Part the Cloud program.